More than two years into the GLP-1 injectable shortage, drugmakers Eli Lilly and Novo Nordisk have asked FDA to take emergency action to prohibit compounding of tirzepatide and semaglutide, the active pharmaceutical ingredients in both the brand-name and compounded GLP-1...